FIELD: medicine, pharmacy.
SUBSTANCE: invention describes valsartan salts chosen from the group involving monosodium, monopotassium, disodium, dipotassium, magnesium, calcium, bis-diethyl (or dipropyl, or dibutyl)-ammonium salts or their hydrates, and mixtures of these salts also. Also, invention relates to a method for their preparing and a pharmaceutical composition comprising thereof. Proposed salts can be in crystalline, partially crystalline, amorphous or polymorphous form. Prepared salts show high quality of crystalline lattices that is a base for chemical and physical stability of new compounds.
EFFECT: improved preparing method, improved and valuable properties of salts.
11 cl, 11 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| HYDRATES OF SALTS OF ALKALINE-EARTH METALS AND IRBESARTAN AND PREPARATION THEREOF | 2006 |
|
RU2401266C2 |
| ALISKIREN AND OROTIC ACID SALT | 2007 |
|
RU2456267C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| SALT OF ALISKIREN AND SULFURIC ACID | 2007 |
|
RU2439054C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
| TOSYLATE SALT OF THERAPEUTIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 2008 |
|
RU2430099C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| S-OMEPRAZOLE STRONTIUM SALT OR HYDRATE THEREOF, METHOD OF PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS | 2006 |
|
RU2372345C1 |
